Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

P. Petrylak, Daniel; W. Kantoff, Philip; J. Vogelzang, Nicholas; Mega, Anthony; T. Fleming, Mark; Stephenson, Joe; C. Frank, Richard; D. Shore, Neal; Dreicer, Robert; F. McClay, Edward; R. Berry, William; Agarwal, Manish; A. DiPippo, Vincent; Rotshteyn, Yakov; Stambler, Nancy; C. Olson, William; Morris, Stephen; J. Israel, Robert

doi:10.1002/pros.23765

Public

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Published in The Prostate • Jan 20, 2019

Authors:

Daniel P. Petrylak

Philip W. Kantoff

Nicholas J. Vogelzang

Abstract

BACKGROUND: Prostate-specific membrane antigen (PSMA) is a well-characterized target that is overexpressed selectively on prostate cancer cells. PSMA antibody-drug conjugate (ADC) is a fully human IgG1 monoclonal antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE),...

Subject

Medicine

Prostate cancer

Pharmacokinetics

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!